The Readout Loud
The Readout Loud

Nov 13, 2026 · 19 min

Heart drug failures test genetics-led discovery

421: The future of heart drug research in the wake of study setbacks

The setbacks raise questions about whether genetically validated targets can reliably produce effective cardiovascular medicines.

3 key takeaways
  1. 1Trials targeting Lp(a) and IL-6 showed that biological target engagement does not guarantee cardiovascular benefit.
  2. 2Cardiovascular drug development remains unusually difficult because it demands long timelines, costly studies, and challenging clinical endpoints.
  3. 3Genetics will remain central to drug discovery, but the failures underscore the need for greater humility about biological complexity.

Don't miss

Matthew Herper argues that failed Lp(a) and IL-6 trials should prompt humility about genetics, not abandonment of genetic evidence.

The brief

The episode opens with a run of biotech setbacks: safety questions around Vertex’s povetacicept, tumor reports involving Novartis’s Zolgensma, and declining confidence in Alnylam.

The central discussion asks why trials aimed at genetically validated Lp(a) and IL-6 pathways failed to deliver meaningful cardiovascular benefit despite successful target engagement.

Matthew Herper explains why heart-drug development is especially punishing: studies take years, cost heavily, rely on difficult endpoints, and compete with declining investment.

The failures do not discredit genetics, but they do challenge the assumption that human genetic evidence can predict drug efficacy without accounting for biology’s complexity.

What was said on this episode

27 statements · 8 positive · 17 negative · 2 mixed

  1. Adam Feuersteinon Vertex POVYPositive2:26

    FDA approval of Vertex’s POVY is highly likely

    “the FDA is almost certainly going to approve this vertex drug”

    Listen at 2:26

  2. Adam Feuersteinon U.S. IgA nephropathy treatment marketPositive2:50

    The U.S. IgA nephropathy treatment market is worth about $20 billion

    “this treatment market is worth about $20 billion in the U.S. alone”

    Listen at 2:50

  3. Adam Feuersteinon IgA nephropathy drugsNegative3:00

    Competition among the three IgA nephropathy drugs will be intense

    “Competition between these three drugs is going to be intense.”

    Listen at 3:00

  4. Adam Feuersteinon Vertex POVYNegative3:14

    POVY’s infection concerns could reduce its attractiveness versus competitors

    “that could make it a less attractive option compared to the competitors.”

    Listen at 3:14

  5. Elaine Chenon ZolgensmaNegative5:18

    Two Zolgensma-associated tumor cases may be linked to treatment

    “two to date have showed evidence that the tumors may be linked to the treatment itself.”

    Listen at 5:18

  6. Elaine Chenon ZolgensmaNegative6:02

    The FDA is investigating Zolgensma’s tumor risk

    “the FDA is investigating.”

    Listen at 6:02

  7. Adam Feuersteinon NileNegative7:29

    Alnylam’s current valuation is about $20 billion

    “today Al Nilem is a $20 billion company.”

    Listen at 7:29

  8. Elaine Chenon AmvuttraNegative8:09

    Alnylam is struggling to increase Amvuttra prescriptions

    “Alnylam is struggling with getting more prescriptions.”

    Listen at 8:09

  9. Amvuttra is a blockbuster drug

    “Amputra is a blockbuster drug.”

    Listen at 8:14

  10. Adam Feuersteinon Alnylam stockNegative8:37

    Uncertainty about Amvuttra sales mostly caused Alnylam’s stock collapse

    “the company's inability to forecast Amutra sales moving forward, I think that's been mostly responsible for the stock's collapse.”

    Listen at 8:37

  11. Adam Feuersteinon AlnylamNegative8:46

    Alnylam will not recover until sales meet expectations for two or three quarters

    “the company is not going to turn around until it can string together two or three quarters of sales performance that meet or exceed investor expectations.”

    Listen at 8:46

  12. Matthew Herperon Heart attacks and strokesNegative10:33

    Heart attacks and strokes are the largest killers in the developed world

    “these are the largest killers in the developed world.”

    Listen at 10:33

  13. Matthew Herperon Genetic target validationNegative11:32

    Genetic evidence does not guarantee that lowering a target pharmacologically improves patients

    “having those genetic data don't tell you that giving somebody a drug and lowering it is going to make them better.”

    Listen at 11:32

  14. Matthew Herperon Genetic drug-target validationNegative12:08

    Genetic validation can still incorrectly predict drug efficacy

    “you can still be wrong.”

    Listen at 12:08

  15. Matthew Herperon GLP-1 receptor agonistPositive13:15

    GLP-1 and other diabetes drugs have shown unexpected cardiovascular benefits

    “Over the past decade or so, they're diabetes drugs. They're the GLP-1s. There are other medicines that have shown a surprise cardiovascular benefit.”

    Listen at 13:15

  16. Matthew Herperon Cardiovascular drug studiesNegative13:49

    Cardiovascular drug studies take a long time and are very expensive

    “these studies take a long time, and they're super expensive.”

    Listen at 13:49

  17. Matthew Herperon Cardiovascular drug developmentNegative14:21

    Biotech and pharma companies have already reduced cardiovascular drug development

    “they already have cut back.”

    Listen at 14:21

  18. Matthew Herperon Cardiovascular biotech innovationNegative15:11

    Cardiovascular biotech may lack the innovation engine seen elsewhere

    “my worry is really just that we don't get that innovation engine that we get in other parts of biotech.”

    Listen at 15:11

  19. Matthew Herperon Genetics in drug discoveryPositive15:36

    Drug companies will continue using genetics to find drug targets

    “no one's going to just stop using genetics. to find drug targets.”

    Listen at 15:36

  20. Matthew Herperon Drug development biologyNegative16:19

    Drug development biology will prove more complicated than expected

    “It's going to be more complicated than you think.”

    Listen at 16:19

  21. Matthew Herperon biologyNegative16:26

    Biology is highly complex and difficult to predict

    “Biology is maddeningly complex.”

    Listen at 16:26

  22. Matthew Herperon Genetics and AI drug-discovery toolsPositive16:38

    Future genetics-and-AI tools may reduce drug failure rates below one in ten

    “we won't have one out of every 10 drugs fail.”

    Listen at 16:38

  23. Matthew Herperon Drug development programsNegative17:21

    Drug developers should lower estimated probabilities of success

    “I would expect everyone to have taken their probability of success on everything down.”

    Listen at 17:21

  24. Matthew Herperon Lp(a)-lowering drugsMixed17:28

    Lowering Lp(a) fully may be necessary to produce cardiovascular benefit

    “maybe you need to get LP little a all the way down in order to have an effect.”

    Listen at 17:28

  25. Matthew Herperon Lp(a)-lowering drugsMixed17:36

    Lp(a) drugs may work better in high-risk patients before a first heart attack

    “maybe you need to be in a different population, like people who have high risk but don't have their first heart attack.”

    Listen at 17:36

  26. Matthew Herperon Inflammation-targeting cardiovascular drugsPositive17:52

    A correctly targeted inflammation drug could become highly successful

    “if you find the right target, you're going to have a huge drug.”

    Listen at 17:52

  27. Matthew Herperon Cardiovascular drug marketPositive18:10

    The cardiovascular drug market is large and companies will pursue it

    “there's a huge market here and companies will chase it.”

    Listen at 18:10

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.